22 October 2015
EMA/CHMP/679659/2015
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Edurant

rilpivirine

On 22 October 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Edurant. The marketing authorisation holder for this medicinal product is Janssen-Cilag International N.V.

The CHMP adopted an extension to the existing indication as follows[2]:

> "EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve ~~adult~~ patients **12 years of age and older** with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
>
> As with other antiretroviral medicinal products, genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1)."

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact